title: [Economic assessment of the use of biological medications in military medicine].
abstract: By the example of rheumatoid arthritis was considered the methods of economic assessment of advisability of modern biological medication usage in military medicine. The usage of these medications leads to quick clinical response, decrease of the additional medication intake, decrease of the average duration of treatment, "move aside" time of permanent disablement. Modern active therapy can increase the effectiveness of treatment; improve the quality of life, decrease the average duration of hospital stay, following treatment expense and welfare payment for this category of ill.
authors.forename: A B
authors.initials: AB
authors.lastname: Belevitin
authors.forename: V V
authors.initials: VV
authors.lastname: Tyrenko
authors.forename: O A
authors.initials: OA
authors.lastname: Grigor'eva
authors.forename: S G
authors.initials: SG
authors.lastname: Bologov
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000191:economics; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D000069285:Infliximab; D008887:Military Medicine / Q000191:economics*; D008889:Military Personnel; D000069283:Rituximab; D012426:Russia
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D000069285:Infliximab; D000068879:Adalimumab